The direct Myc target Pim3 cooperates with other Pim kinases in supporting viability of Myc-induced B-cell lymphomas

Linus Plym Forshell; Yongmei Li; Tacha Zi Plym Forshell; Martina Rudelius; Lisa Nilsson; Ulrich Keller; Jonas Nilsson

doi:10.18632/oncotarget.283

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

The direct Myc target Pim3 cooperates with other Pim kinases in supporting viability of Myc-induced B-cell lymphomas

Linus Plym Forshell, Yongmei Li, Tacha Zi Plym Forshell, Martina Rudelius, Lisa Nilsson, Ulrich Keller and Jonas Nilsson _

PDF | HTML | How to cite

Oncotarget. 2011; 2:448-460. https://doi.org/10.18632/oncotarget.283

Metrics: PDF 3753 views | HTML 5211 views | ?

Abstract

Linus Plym Forshell¹, Yongmei Li^1,2,*, Tacha Zi Plym Forshell^{1, *}, Martina Rudelius³, Lisa Nilsson¹, Ulrich Keller⁴ and Jonas Nilsson¹

¹ Department of Molecular Biology, Umeå University, Umeå, Sweden

²Department of Medical Microbiology, Tianjin Medical University, Tianjin, People's Republic of China

³Department of Pathology, Technical University of Munich, Munich, Germany

⁴Department of Medicine, Technical University of Munich, Munich, Germany

^*Denotes equal contribution

Keywords: cancer, lymphoma, oncogenes, c-Myc, Pim-3

Received: June 1, 2011; Accepted: June 2, 2011; Published: June 5, 2011;

Correspondence:

Jonas Nilsson, e-mail:

Abstract

The Pim kinases are weak oncogenes. However, when co-expressed with a strong oncogene, such as c-Myc, Pim kinases potentiate the oncogenic effect resulting in an acceleration of tumorigenesis. In this study we show that the least studied Pim kinase, Pim-3, is encoded by a gene directly regulated by c-Myc via binding to one of the conserved E-boxes within the Pim3 gene. Accordingly, lymphomas arising in Myc-transgenic mice and Burkitt lymphoma cell lines exhibit elevated levels of Pim-3. Interestingly, inhibition of Pim kinases by a novel pan-Pim kinase inhibitor, Pimi, in Myc-induced lymphoma results in cell death that appears independent of caspases. The data indicate that Pim kinase inhibition could be a viable treatment strategy in certain human lymphomas that rely on Pim-3 kinase expression.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 283

Publication Alerts

Research Papers:

The direct Myc target Pim3 cooperates with other Pim kinases in supporting viability of Myc-induced B-cell lymphomas

Abstract